Form 4: Enliven Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold shares of common stock on April 21, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 21, 2025, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 15, 2024.
• Two transactions occurred: one involving 4,670 shares at a weighted average price of $16.0274, and another involving 330 shares at a weighted average price of $16.7208.
• Following these transactions, Lyssikatos indirectly owns 997,688 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions without expressing any opinion on the company's performance or future prospects. The use of a 10b5-1 plan suggests the sales were pre-planned.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative.

Stakeholder Impact

• The stock sale by a key executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Enliven Therapeutics, ELVN, insider trading, Form 4, Lyssikatos, Rule 10b5-1, stock sale, Chief Scientific Officer